BACKGROUND: The relationship between metabolic syndrome (MetS), male hypogonadism and their possible interaction in cardiovascular (CV) risk stratification are not completely understood. AIM: We reviewed relationships between testosterone (T) and MetS emphasizing their possible interaction in the pathogenesis of CV diseases. MATERIALS AND METHODS: A systematic search of published evidence was performed using Medline (1969 to January 2011). RESULTS: Cross-sectional data have shown that subjects with MetS have lower levels of total T (TT) (about 3 nmol/l), as hypogonadism is more evident in subjects with than in those without erectile dysfunction (ED) than in those without. Longitudinal evidence shows that low T is allocated with a higher risk of subsequent development of MetS, although the reverse condition is also possible. Which are the factors in MetS responsible for the low T is not completely clarified. In clinical studies, increased waist circumference is the major determinant of MetS-associated hypogonadism. Our experiments in rabbits do not support the idea that visceral fat is the main determinant of MetS-associated male hypogonadism. Only few randomized clinical trials have evaluated the impact of T replacement therapy (TRT) in patients with MetS. Available evidence suggests that TRT decreases visceral fat accumulation and ameliorates insulin sensitivity, whereas androgen deprivation increases abdominal adiposity. CONCLUSIONS: The clinical significance of the MetS-associated hypogonadism needs further clarifications. In particular, it has not been completely clarified if low T might be considered a cause or a consequence of MetS. The benefit of TRT in term of the reduction of CV risk needs to be confirmed in larger and longer studies.
BACKGROUND: The relationship between metabolic syndrome (MetS), male hypogonadism and their possible interaction in cardiovascular (CV) risk stratification are not completely understood. AIM: We reviewed relationships between testosterone (T) and MetS emphasizing their possible interaction in the pathogenesis of CV diseases. MATERIALS AND METHODS: A systematic search of published evidence was performed using Medline (1969 to January 2011). RESULTS: Cross-sectional data have shown that subjects with MetS have lower levels of total T (TT) (about 3 nmol/l), as hypogonadism is more evident in subjects with than in those without erectile dysfunction (ED) than in those without. Longitudinal evidence shows that low T is allocated with a higher risk of subsequent development of MetS, although the reverse condition is also possible. Which are the factors in MetS responsible for the low T is not completely clarified. In clinical studies, increased waist circumference is the major determinant of MetS-associated hypogonadism. Our experiments in rabbits do not support the idea that visceral fat is the main determinant of MetS-associated male hypogonadism. Only few randomized clinical trials have evaluated the impact of T replacement therapy (TRT) in patients with MetS. Available evidence suggests that TRT decreases visceral fat accumulation and ameliorates insulin sensitivity, whereas androgen deprivation increases abdominal adiposity. CONCLUSIONS: The clinical significance of the MetS-associated hypogonadism needs further clarifications. In particular, it has not been completely clarified if low T might be considered a cause or a consequence of MetS. The benefit of TRT in term of the reduction of CV risk needs to be confirmed in larger and longer studies.
Authors: Piero Montorsi; Paolo M Ravagnani; Stefano Galli; Andrea Salonia; Alberto Briganti; José P Werba; Francesco Montorsi Journal: Eur Urol Date: 2006-07-28 Impact factor: 20.096
Authors: Giovanni Corona; Edoardo Mannucci; Luisa Petrone; Claude Schulman; Giancarlo Balercia; Alessandra D Fisher; Valerio Chiarini; Gianni Forti; Mario Maggi Journal: J Sex Med Date: 2007-05 Impact factor: 3.802
Authors: Steven M Petak; Howard R Nankin; Richard F Spark; Ronald S Swerdloff; Luis J Rodriguez-Rigau Journal: Endocr Pract Date: 2002 Nov-Dec Impact factor: 3.443
Authors: Rémy Burcelin; Bernard Thorens; Micheline Glauser; Rolf C Gaillard; François P Pralong Journal: Endocrinology Date: 2003-07-03 Impact factor: 4.736
Authors: G Corona; V A Giagulli; E Maseroli; L Vignozzi; A Aversa; M Zitzmann; F Saad; E Mannucci; M Maggi Journal: J Endocrinol Invest Date: 2016-05-30 Impact factor: 4.256
Authors: Katya B Rubinow; Jing H Chao; Derek Hagman; Mario Kratz; Brian Van Yserloo; Nilesh W Gaikwad; John K Amory; Stephanie T Page Journal: Am J Physiol Endocrinol Metab Date: 2017-07-11 Impact factor: 4.310
Authors: E Maseroli; G Rastrelli; G Corona; V Boddi; A M L Amato; E Mannucci; G Forti; M Maggi Journal: J Endocrinol Invest Date: 2014-02-11 Impact factor: 4.256
Authors: Biljana Musicki; Anthony J Bella; Trinity J Bivalacqua; Kelvin P Davies; Michael E DiSanto; Nestor F Gonzalez-Cadavid; Johanna L Hannan; Noel N Kim; Carol A Podlasek; Christopher J Wingard; Arthur L Burnett Journal: J Sex Med Date: 2015-12-08 Impact factor: 3.802